Maze Therapeutics (MAZE) awards director 36K stock options

Rhea-AI Filing Summary

Maze Therapeutics director Paula A. Johnson received a grant of stock options for 36,000 shares of common stock. The options have an exercise price of $27.665 per share, expire on August 12, 2036, and vest in 36 equal monthly installments starting September 13, 2026, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Johnson Paula A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	36,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 36,000 shares (Direct)

Footnotes (1)

1. F1. The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Options Granted: 36,000 shares Exercise Price: $27.665 per share Underlying Shares: 36,000 shares +4 more

7 metrics

Options Granted 36,000 shares Stock Option (Right to Buy) granted to Paula A. Johnson

Exercise Price $27.665 per share Conversion or exercise price of the stock option

Underlying Shares 36,000 shares Underlying common stock tied to the option grant

Total Options After Grant 36,000 shares Total derivative securities owned following the transaction

Option Expiration Date August 12, 2036 Expiration date of the stock option grant

Vesting Start Date September 13, 2026 Date first 1/36th of the option award vests

Vesting Schedule Length 36 months Monthly vesting in 1/36th tranches, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, underlying security, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 27.6650"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The option shall vest as to 1/36th of the total award monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transaction did MAZE report for Paula A. Johnson on this Form 4?

Maze Therapeutics (MAZE) reported that director Paula A. Johnson received a grant of 36,000 stock options. These options relate to Maze common stock and are structured as a compensation award rather than an open-market purchase or sale.

What is the exercise price of the stock options granted to Paula A. Johnson at MAZE?

The stock options granted to Paula A. Johnson carry an exercise price of $27.665 per share. This is the price she must pay per share to purchase Maze Therapeutics common stock if she exercises the options after they vest.

How do the 36,000 MAZE stock options granted to Paula A. Johnson vest?

The 36,000 Maze Therapeutics stock options vest in 36 equal monthly installments. The first 1/36th tranche vests on September 13, 2026, with each remaining tranche vesting monthly thereafter, subject to her continued service to the company.

When do Paula A. Johnson’s MAZE stock options expire?

Paula A. Johnson’s Maze Therapeutics stock options expire on August 12, 2036. She may only exercise vested portions of the option before this expiration date, consistent with the terms of the grant and her continued service requirements.

How many MAZE options does Paula A. Johnson hold after this reported grant?

After this transaction, Paula A. Johnson is reported to hold 36,000 stock options directly. These options are linked to 36,000 shares of Maze Therapeutics common stock as the underlying security, assuming they vest and are exercised in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 04:51 PM Accepted by SEC EDGAR 08/17/2026 - 04:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Paula A

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.665	08/13/2026		A		36,000		(1)	08/12/2036	Common Stock	36,000	$0	36,000	D

Explanation of Responses:

1. The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)